Ladarixin With Sotorasib in Advanced NSCLC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Ladarixin With Sotorasib in Advanced NSCLC — Stella

Home/Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation/

View on ClinicalTrials.gov

Recruiting

Back to Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(6 sites)

United States

NYU Langone Health, Garden City, New York

NYU Langone Health, Mineola, New York

NYU Langone Health, New Hyde Park, New York

NYU Langone Health, New York, New York

NYU Langone Health, New York, New York

NYU Langone Health, New York, New York

Key details

Phase

Early testing

Sponsor

NYU Langone Health

Enrollment target

~40 participants

Started

August 2023

Primary completion

August 2027

Age range

18 Years – 100 Years

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.